Boston Scientific Again Cuts 2026 Guidance

'Not the outcome we planned:' Boston Scientific revenue outlook drops, plans cost cuts.

The company's cardiovascular business faces new rivals in pulsed field ablation and heart devices. A restructuring plan aims to cut $500 million in annual expenses.

Boston Scientific again cuts 2026 guidance

Challenges in the electrophysiology and Watchman businesses led the medtech company to cut its sales and earnings per share forecasts for the second quarter in a row.

Boston Scientific revenue outlook drops, layoffs expected

Boston Scientific is once again dropping its outlook for 2026 amid challenges among key revenue drivers. The Marlborough firm started off 2026 by saying its net sales growth would be 10% to 11% on an organic basis. That range dropped to 6.5% and 8% a few months ago, and was reduced to 5% to 6% on Wednesday. More on this story from Boston Business Journal